Results 181 to 190 of about 37,430 (216)
Some of the next articles are maybe not open access.
The Pharmaceutical Journal, 2014
Lenalidomide is an immunomodulatory drug (IMiD), which is well established and approved in the treatment of multiple myeloma (MM) and 5q-myelodysplastic syndrome (MDS). The mode of action includes immune modulation, anti-angiogenetic, anti-inflammatory, and anti-proliferative effects.
Katja, Weisel, Lothar, Kanz
+5 more sources
Lenalidomide is an immunomodulatory drug (IMiD), which is well established and approved in the treatment of multiple myeloma (MM) and 5q-myelodysplastic syndrome (MDS). The mode of action includes immune modulation, anti-angiogenetic, anti-inflammatory, and anti-proliferative effects.
Katja, Weisel, Lothar, Kanz
+5 more sources
Current Treatment Options in Oncology, 2007
The standard treatment approach to symptomatic myeloma consists of induction therapy, consolidation with high-dose chemotherapy and autologous hematopoietic stem cell transplantation in appropriate patients, maintenance therapy, and salvage therapy. Salvage therapy is of particular importance because not all patients respond to primary therapy, and ...
Seema, Singhal, Jayesh, Mehta
openaire +2 more sources
The standard treatment approach to symptomatic myeloma consists of induction therapy, consolidation with high-dose chemotherapy and autologous hematopoietic stem cell transplantation in appropriate patients, maintenance therapy, and salvage therapy. Salvage therapy is of particular importance because not all patients respond to primary therapy, and ...
Seema, Singhal, Jayesh, Mehta
openaire +2 more sources